Wednesday, April 29, 2015 1:17:42 AM
Opdivo, which is used to treat advanced melanoma and was more recently approved to treat a common form of lung cancer, had sales of $40 million in the quarter. Merck on Tuesday said it Keytruda, a similar new drug that helps the immune system to fight cancer, had first quarter sales of $83 million.
"Opdivo sales of $40 million is a little disappointing. We expected $54 million," BMO Capital Markets analyst Alex Arfaei said in a note. Arfaei said he expects a strong Opdivo launch in the much larger lung cancer market as the year progresses.
Bristol is counting on potential multibillion-dollar sales of its immunotherapy cancer drugs to help drive future growth. Yervoy, an older immunotherapy for melanoma, saw sales rise 20 percent to $325 million.
Bristol-Myers posted better-than-expected quarterly results for the quarter, helped by cost cuts and a higher estimate of royalties owed the company from sales of its Abilify schizophrenia treatment.
The U.S. drugmaker said it earned $1.19 billion, or 71 cents per share, in the first quarter. That compared with $937 million, or 56 cents per share, in the year-earlier period.
Excluding special items, Bristol-Myers earned 71 cents per share, well above the average forecast of 51 cents per share, according to Thomson Reuters I/B/E/S. Results were helped by lower spending on marketing and advertising.
Company sales rose 6 percent to $4.04 billion, about $200 million above Wall Street expectations. They would have risen 13 percent if not for the stronger dollar, which lowers the value of sales abroad.
Bristol-Myers raised the lower end of its full-year 2015 profit forecast by five cents, to $1.60 per share, while keeping the higher end at $1.70.
Sales of Abilify rose 3 percent to $554 million, but would have been far lower if not for a recalculation of royalties Bristol-Myers receives from partner Otsuka Holdings Co.
Under a marketing agreement that ended April 20, Bristol-Myers last year recorded sales of Abilify that reflected an estimated 33 percent royalty rate. But in the recent first quarter, Bristol-Myers recorded sales that reflected an actual 50 percent royalty.
Bristol-Myers shares were off $1.25, or 1.9 percent, at $63.91 on the New York Stock Exchange.
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
FEATURED DaBaby and Stunna 4 Vegas's "NO DRIBBLE" Joins Music Licensing, Inc.'s Portfolio • Jun 7, 2024 10:15 AM
Mushrooms Inc. (OTC: MSRM) Announces Significant Share Buy Back by the Board Director and New Strategic Initiatives. • MSRM • Jun 5, 2024 1:32 PM
Hydromer Announces Launch of HydroThrombX Medical Device Coating Technology • HYDI • Jun 5, 2024 10:24 AM
Dr. Michael Dent Finances $1 Million to Drive HealthLynked's Healthcare Transformation • HLYK • Jun 5, 2024 8:00 AM
Avant Technologies Enters Binding LOI to Purchase Dozens of High-Performance, Immersible, AI-Powered Servers • AVAI • Jun 5, 2024 8:00 AM
IQST - iQSTEL Announces $290 Million 2024 Annual Revenue Forecast • IQST • Jun 4, 2024 1:43 PM